Global Medical Marijuana Market to Reach 55.8 Billion by 2025, New Research
I know I am late to the party here, but with the Kim Ogg ruling the other day. I dont really see how the industry could get smaller.
Personally I think there is big growth potential, primarily in the medical field and in vaping. From the list that yall provided I like the MCIG and VPCO. TRTC being on the equipment side I think they could be positioned well too.
Anyone looked at Arc view at all?
I sold 2,000,000 shars of VPCO due to no activity. MCIG is a good bet as well as PURA, PMCB, FFRMF and CBIS. The hot one for me lately is SING, pulled in $2500 over the last two days. But, like everything else, what goes up will likely come down.
Your link on post 18 had some good info and companies.
I am not set up for day trading, mainly because my work blocks pretty much all websites that pertain to it. I am more looking to make some longer term investments on well positioned companies with lots of growth potential. No expert here but looking at some of the balance sheets and cash flows is a bit scary, everyone seems to be cash flow negative.
Stay tuned! :)
First Ever Cannabis-Based ETF to Include PharmaCyte Biotech, Abbott Laboratories, and GW Pharmaceuticals
NEW YORK, NY--(Marketwired - February 23, 2017) - PharmaCyte Biotech (OTCQB: PMCB) will join GW Pharmaceuticals, Abbott Laboratories and 66 other publicly traded companies in what could be the first ever cannabis exchange-traded fund (ETF) -- the Emerging AgroSphere ETF. One week ago, ETF Managers Group, headquartered in Summit, New Jersey, filed an initial registration statement with the SEC to become the first of its kind in the ETF industry (https://www.sec.gov/Archives/edgar/data/1467831/000114420417009539/v459698_485apos.htm).
According to the filing, the proposed fund will be focused on medical cannabis and "will not invest in any companies that are focused on serving the non-medical marijuana market in the United States, Canada or any other country unless and until such time as the production and sale of non-medical marijuana becomes legal in the United States, Canada or such other country, respectively."
Now ETF Managers Group will wait for the SEC to approve the fund, and, if approved, investors can own a piece of the 69 companies that make up the proposed fund all under one ETF. This, of course, means that fund managers will need to buy up shares of the companies that make up the fund, which should increase the liquidity of each of these companies. The index composition can be viewed at: https://www.solactive.com/indices/?indexmembers=DE000SLA1CR1
PharmaCyte Biotech, GW Pharmaceuticals, Abbot Laboratories, Cannabis Science Inc., Medical Marijuana Inc. and the 64 other companies that will make up the proposed ETF, will fall into one of the following three categories. The companies will either be (i) engaged in lawful medical research intended to lead to the production of government approved prescription drugs which utilize natural or synthetic versions of the cannabinoid, cannabidiol (CBD), and other cannabis based extracts, (ii) involved in the production or sale of products which are legal derivatives of industrial hemp, or (iii) involved in the supply chain of either category of company.
PharmaCyte Biotech's work in medical cannabis began when it acquired an exclusive, worldwide license to use its Cell-in-a-Box® technology in combination with genetically modified non-stem cell lines which are designed to activate cannabinoid molecules for development of treatments for diseases and their related symptoms.
In contrast to the work being done by PharmaCyte's competitors, the company plans to combine the Cell-in-a-Box® live-cell encapsulation technology with cannabinoids to develop a unique therapy for difficult-to-treat and deadly forms of cancer, such as brain cancer. Some cannabinoids are prodrugs that must be converted into their cancer-killing form. These prodrugs will be used with the Cell-in-a-Box® technology in ways that optimize their anticancer properties while minimizing or even eliminating adverse side effects that normally occur with chemotherapy to treat cancer.
PharmaCyte says that it plans to focus initially on developing specific therapies based on carefully chosen cannabinoid molecules rather than using complex Cannabis extracts. The company believes an understanding of the chemical and biochemical processes involved in the interaction of substances derived from Cannabis with live-cell encapsulation will provide the opportunity to develop targeted "green" approaches to treating cancers, such as pancreatic, brain, breast and prostate, among others.
PharmaCyte entered into a Research Agreement with the University of Northern Colorado (UNC). The goal of the ongoing research at UNC is to develop methods for the identification, separation and quantification of cannabinoids (which will act like prodrugs) that the company says may be used in combination with its Cell-in-a-Box® technology to treat various diseases, beginning with brain and pancreatic cancers.
Initial studies were undertaken at UNC on behalf of PharmaCyte using "cannabinoid-like" model compounds to identify the appropriate cell type that can convert the selected cannabinoid prodrugs into metabolites with anticancer activity. UNC is now working with cannabinoid prodrugs from Cannabis to identify the appropriate cell type for the same purpose. Once identified, the genetically modified cells that will produce the appropriate enzyme to convert the cannabinoid prodrugs will be encapsulated using PharmaCyte's Cell-in-a-Box® technology. The encapsulated cells and cannabinoid prodrugs identified by these studies will then be combined and used for future studies to evaluate their anticancer effectiveness.
All of my investment are long term, I'm not day trading.
some good info
CARA Pharmaceuticals. I'm long on this one but it's had some great success the past 6mos. 1yr outlook is low $20s.
I have been looking for a mutual fund or ETF in this field. While there is not an ETF (Exchange traded fund) out yet but it looks like one is in the works, there is (1) mutual fund out there. Now, this mutual fund has not been good thus far. American Growth Fund Series Two (AMREX)
As of Oct 2016 it had 25% in cash which is high. Not sure where it is at today.
One thing you can do is look at their top holdings and possibly buy some of the individual companies themselves.
Top 25 Holdings: Oct 2016
Dec 2016 top 10 Holdings http://www.agfseries2.com/portfolio
For those looking for more companies to choose this may help! By no means am I saying use this mutual fund. Just wanted to point out this is the only one out there. Many times I find good mutual funds in other sectors and see what they own, then I may personally buy some of their top 5 holdings. Good luck!
I honestly would not recommend getting into cannabis stocks with the tone in the last week from the current administration. It sounds like they are going to give us some more s--t so I would think to look to invest until after they've shown what they are going to do to us!! hopefully not much, the industry is so far in full swing it would be so stupid to stop it. billions in revenue and hundreds of thousands of jobs, who wouldnt love it!?
I reached out to a guy I went to school with, who is pretty involved in the industry. Above is what he sent me. I figure Trump is a business man and will leave it up to the states in the end, versus trying to crack down.
Just passing it along but also wanted to see what others takes are.
How did your pot stocks do in 2017?
I'm up about 60% (avg) overall on 14 stocks.
My top 5
the other 9 stocks are gaining
I think 2018 is going to be a stellar year.
|All times are GMT -5. The time now is 09:22 AM.|
Powered by vBulletin® Version 3.8.8
Copyright ©2000 - 2020, vBulletin Solutions, Inc.
Resources saved on this page: MySQL 14.29%
vBulletin Optimisation provided by vB Optimise (Pro) - vBulletin Mods & Addons Copyright © 2020 DragonByte Technologies Ltd.
vBulletin Security provided by vBSecurity v2.2.2 (Pro) - vBulletin Mods & Addons Copyright © 2020 DragonByte Technologies Ltd.